Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Thats a big unknown
Phase 2 results at 48 weeks (Jastreboff et al., NEJM 2023): Phase 3 TRIUMPH-4 at 68 weeks (Lilly Press Release, Dec 2025): The 12 mg dose produced 28.7% body weight loss, an average of 71.2 lbs from a 248.5 lb baseline
Nonalcoholic fatty liver disease and metabolic syndrome: shared genetic basis of pathogenesis
Joshi D, OGrady J, Patel A, Shawcross D, Connor S, Deasy N, Willars C, et al
doi: 10.3389/fimmu.2026.1734880 Received 29 October 2025 Revised 06 March 2026 Accepted 09 March 2026 Published 30 March 2026 Volume 17 - 2026 Edited by Liping Feng, Duke University, United States Reviewed by Akihiro Nakamura, Kyoto Prefectural University of Medicine, Japan Simn Quetzalcoatl Rodrguez-Lara, Tecnologico de Monterrey Campus Puebla, Mexico Updates Copyright 2026 Wang, Wang, Ji, Lou, Yuan, Cui, Xiang and Zhou